论文部分内容阅读
近10多年的研究已确认阿斯匹林(ASA)是一有效的抗血栓药物,其作用机理为抑制血小板功能。ASA不可逆地抑制血小板中的环氧化酶至终身,阻断花生四烯酸转化成ThromboxaneA_2(TXA_2),后者有使血小板聚集和血管收缩作用。ASA也抑制血管壁细胞生成Prostacyclin(PGI_2),而PGI_2具有抗血小板聚集和扩血管作用。因此,ASA具有抗血栓和致血栓两种潜力。一些大组临床试验,证实ASA_1～1.5
Nearly 10 years of research has confirmed that aspirin (ASA) is a potent antithrombotic drug whose mechanism of action is to inhibit platelet function. ASA irreversibly inhibits cyclooxygenase activity in platelets and blocks the conversion of arachidonic acid to Thromboxane A2 (TXA2), which has platelet aggregation and vasoconstriction. ASA also inhibits the production of Prostacyclin (PGI_2) in vascular wall cells, whereas PGI_2 has anti-platelet aggregation and vasodilator effects. Therefore, ASA has both anti-thrombotic and thrombotic potential. Some large group of clinical trials, confirmed ASA_1 ~ 1.5